IFNA1 and in situ carcinoma: W: women; M: male; CLAD: cladribine; SD: standard deviation; RIS: radiologically isolated syndrome; CIS: clinically isolated syndrome; RR: relapsing-remitting; SPa: active secondary progressive; SP: secondary progressive; EDSS: Expanded Disability Status Scale; ARR: annualized relapse rate; Gd+: gadolinium-enhancing lesions; DMT: disease-modifying therapy; IFN/GA: interferon/glatiramer acetate; TER/DMF: teriflunomide/dimethyl fumarate; FTY: fingolimod; NTZ: natalizumab; RTX/OCR: rituximab/ocrelizumab; ALEM: alemtuzumab; CYC: cyclophosphamide